Denali Therapeutics, Inc. logo

Denali Therapeutics, Inc.

Denali Therapeutics is a biotechnology firm that focuses on the therapeutic discovery and development to treat neurodegenerative diseases. Denali Therapeutics, is a biotech company, focused on the discovery and development of therapies for patients with neurodegenerative diseases, including Alzheimers disease, Parkinsons disease, ALS and others.

Denalis cofounders includes Ryan Watts, former Director of the Dept. Neuroscience at Genentech, Alexander Schuth, former Director and Head of Neuroscience Partnering at Genentech & Marc Tessier-Lavigne, President of The Rockefeller University.

[stock_market_widget type=”leaderboard” template=”color-frame” color=”yellow” assets=”DNLI” api=”yf” style=”font-size: 15px”]

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://denalitherapeutics.com
Founded2015
Disease Focus
Development Stage
STOCK CODENASDAQ: DNLI
Address
151 Oyster Point Blvd - CA 94080
South San Francisco
United States
Email
contact@dnli.com
Contact Number

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/denali-therapeutics” connections=”true” suffix=””]

In May 2018, Denali acquired all outstanding shares of F-star Gamma, with which it had License and Collaborative Agreement in August 2016. The acquisition expandes its collaboration with F-star on Denalis biologics Transport Vehicle (_TVÓ) blood-brain barrier (_BBBÓ) platform technology. The preclinical data showing its technology advancing across the BBB and into the brain resulted into acquisition and gains right to utilize any of the three BBB transporter Fcab targets nominated by Denali.

In May 2015, Denali Therapeutics, raised $217 Mn in series A financing round. Key Investors includes Fidelity Biosciences, ARCH Venture Partners, Flagship Ventures and the Alaska Permanent Fund.